In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens
Author:
Affiliation:
1. AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA
2. AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom
Abstract
Funder
AstraZeneca
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Link
https://journals.asm.org/doi/pdf/10.1128/AAC.01820-16
Reference14 articles.
1. In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
2. Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
3. Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
4. In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
5. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Case series; Ceftazidime/avibactam for treating post-neurosurgical ventriculitis and meningitis due to Carbapenem-resistant Klebsiella pneumonia (CRKP);Interdisciplinary Neurosurgery;2023-12
2. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme;Journal of Antimicrobial Chemotherapy;2023-09-13
3. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment;Journal of Antimicrobial Chemotherapy;2023-03-08
4. The Dynamics of Antimicrobial Resistance among Enterobacteriaceae Isolates in Russia: Results of the 2012–2018 INFORM and ATLAS International Program Studies;Antibiotics;2022-06-10
5. In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018;The Brazilian Journal of Infectious Diseases;2022-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3